Literature DB >> 23485373

Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.

Anna P Durbin1, Sandra V Mayer, Shannan L Rossi, Irma Y Amaya-Larios, Jose Ramos-Castaneda, Eng Eong Ooi, M Jane Cardosa, Jorge L Munoz-Jordan, Robert B Tesh, William B Messer, Scott C Weaver, Nikos Vasilakis.   

Abstract

Sylvatic dengue viruses (DENV) are both evolutionarily and ecologically distinct from human DENV and are maintained in an enzootic transmission cycle. Evidence of sylvatic human infections from West Africa and Southeast Asia suggests that sylvatic DENV come into regular contact with humans. Thus, this potential of emergence into the human transmission cycle could limit the potential for eradicating this cycle with vaccines currently in late stages of development. We assessed the likelihood of sylvatic DENV-4 emergence in the face of natural immunity to current human strains and vaccination with two DENV-4 vaccine candidates. Our data indicate homotypic neutralization of sylvatic and human DENV-4 strains by human primary convalescent and vaccinee sera but limited heterotypic immunity. These results suggest that emergence of sylvatic strains into the human cycle would be limited by homotypic immunity mediated by virus neutralizing antibodies produced by natural infection or vaccination.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23485373      PMCID: PMC3622939          DOI: 10.1016/j.virol.2013.01.018

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  60 in total

1.  Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells.

Authors:  W D Crill; J T Roehrig
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody.

Authors:  Joseph J B Cockburn; M Erika Navarro Sanchez; Nickolas Fretes; Agathe Urvoas; Isabelle Staropoli; Carlos M Kikuti; Lark L Coffey; Fernando Arenzana Seisdedos; Hugues Bedouelle; Felix A Rey
Journal:  Structure       Date:  2012-01-26       Impact factor: 5.006

3.  Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses.

Authors:  E Wang; H Ni; R Xu; A D Barrett; S J Watowich; D J Gubler; S C Weaver
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.

Authors:  Claudio F Lanata; Teresa Andrade; Ana I Gil; Cynthia Terrones; Omar Valladolid; Betzana Zambrano; Melanie Saville; Denis Crevat
Journal:  Vaccine       Date:  2012-07-31       Impact factor: 3.641

5.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

6.  Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses.

Authors:  Veronique Barban; Jorge L Munoz-Jordan; Gilberto A Santiago; Nathalie Mantel; Yves Girerd; Sandrine Gulia; Jean-Baptiste Claude; Jean Lang
Journal:  Virology       Date:  2012-04-25       Impact factor: 3.616

Review 7.  Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Alexander C Schmidt; Stephen S Whitehead
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

8.  Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.

Authors:  Ruklanthi de Alwis; Scott A Smith; Nicholas P Olivarez; William B Messer; Jeremy P Huynh; Wahala M P B Wahala; Laura J White; Michael S Diamond; Ralph S Baric; James E Crowe; Aravinda M de Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-12       Impact factor: 11.205

9.  Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam.

Authors:  Annette Fox; Nguyen Minh Hoa Le; Cameron P Simmons; Marcel Wolbers; Heiman F L Wertheim; Thi Khuong Pham; Thi Hai Ninh Tran; Thi Minh Lien Trinh; Thi Lien Nguyen; Vu Trung Nguyen; Duc Hien Nguyen; Jeremy Farrar; Peter Horby; Walter R Taylor; Van Kinh Nguyen
Journal:  PLoS Negl Trop Dis       Date:  2011-03-01

Review 10.  Dengue--quo tu et quo vadis?

Authors:  Rubing Chen; Nikos Vasilakis
Journal:  Viruses       Date:  2011-09-01       Impact factor: 5.048

View more
  13 in total

1.  Dengue viruses cluster antigenically but not as discrete serotypes.

Authors:  Leah C Katzelnick; Judith M Fonville; Gregory D Gromowski; Jose Bustos Arriaga; Angela Green; Sarah L James; Louis Lau; Magelda Montoya; Chunling Wang; Laura A VanBlargan; Colin A Russell; Hlaing Myat Thu; Theodore C Pierson; Philippe Buchy; John G Aaskov; Jorge L Muñoz-Jordán; Nikos Vasilakis; Robert V Gibbons; Robert B Tesh; Albert D M E Osterhaus; Ron A M Fouchier; Anna Durbin; Cameron P Simmons; Edward C Holmes; Eva Harris; Stephen S Whitehead; Derek J Smith
Journal:  Science       Date:  2015-09-18       Impact factor: 47.728

Review 2.  Why infectious disease research needs community ecology.

Authors:  Pieter T J Johnson; Jacobus C de Roode; Andy Fenton
Journal:  Science       Date:  2015-09-04       Impact factor: 47.728

3.  Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.

Authors:  Jedhan U Galula; Wen-Fan Shen; Shih-Te Chuang; Gwong-Jen J Chang; Day-Yu Chao
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

4.  Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.

Authors:  Soila Sukupolvi-Petty; James D Brien; S Kyle Austin; Bimmi Shrestha; Sherri Swayne; Kristen Kahle; Benjamin J Doranz; Syd Johnson; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2013-06-19       Impact factor: 5.103

5.  Aedes aegypti NeSt1 Protein Enhances Zika Virus Pathogenesis by Activating Neutrophils.

Authors:  Andrew K Hastings; Ryuta Uraki; Hallie Gaitsch; Khushwant Dhaliwal; Sydney Stanley; Hannah Sproch; Eric Williamson; Tyler MacNeil; Alejandro Marin-Lopez; Jesse Hwang; Yuchen Wang; Jonathan R Grover; Erol Fikrig
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

Review 6.  Flavivirus-mosquito interactions.

Authors:  Yan-Jang S Huang; Stephen Higgs; Kate McElroy Horne; Dana L Vanlandingham
Journal:  Viruses       Date:  2014-11-24       Impact factor: 5.048

7.  Highly divergent dengue virus type 1 genotype sets a new distance record.

Authors:  Alyssa T Pyke; Peter R Moore; Carmel T Taylor; Sonja Hall-Mendelin; Jane N Cameron; Glen R Hewitson; Dennis S Pukallus; Bixing Huang; David Warrilow; Andrew F van den Hurk
Journal:  Sci Rep       Date:  2016-02-29       Impact factor: 4.379

8.  Evaluation of Macaca radiata as a non-human primate model of Dengue virus infection.

Authors:  Fumihiro Kato; Yuki Ishida; Akihiko Kawakami; Tomohiko Takasaki; Masayuki Saijo; Tomoyuki Miura; Takayuki Hishiki
Journal:  Sci Rep       Date:  2018-02-21       Impact factor: 4.379

Review 9.  Complex Roles of Neutrophils during Arboviral Infections.

Authors:  Abenaya Muralidharan; St Patrick Reid
Journal:  Cells       Date:  2021-05-26       Impact factor: 6.600

10.  Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization.

Authors:  Emily N Gallichotte; Thomas J Baric; Usha Nivarthi; Matthew J Delacruz; Rachel Graham; Douglas G Widman; Boyd L Yount; Anna P Durbin; Stephen S Whitehead; Aravinda M de Silva; Ralph S Baric
Journal:  Cell Rep       Date:  2018-10-30       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.